January 23, 2014
Plandaí Sits at the Head of the Medical Marijuana Class
With the announcement of its recent license agreement with Diego Pellicer, Inc. and Diego Pellicer Worldwide Inc., Plandaí Biotechnology, Inc. (OTCQB –PLPL - $0.49 – Spec Buy) has positioned itself at the head of the class in the medical marijuana industry. The license enables Plandaí to use the Diego Pellicer name for its Phytofare™ cannabis extracts in medical and pharmaceutical marijuana applications. Tracing its roots back over one hundred years, the Diego Pellicer name and legacy represents the Rolls Royce of brands in the cannabis industry.
For Plandaí, being able to sell its cannabinoid extracts under the Diego Pellicer moniker will bring tremendous name recognition, branding, and a highly respected status in the medicinal cannabis industry. Moreover, this partnership validates the Company’s Phytofare™ technology, bioavailability and approach to medical marijuana. Clearly, both companies believe this one-two punch will prompt users to be drawn to what could emerge as a leading offering in the space. This outlook is based upon the combination of the power of the Diego Pellicer brand and the Plandaí product’s high bioavailability, which will result in lower dosages and lower costs.
Separately, the news could not come at a better time for Plandaí and its shareholders. In recent days, President Obama has tacitly endorsed the use of marijuana by noting that it is less dangerous than alcohol. Moreover, Proponents of medical marijuana will likely use the 2-week Super Bowl marketing period to flood the media with stories on the topic, placing it near the top of the talking points food chain. Of course it doesn’t hurt that the two Super Bowl representatives are from the two states that have legalized marijuana. After all, exceeding all expectations, Colorado pot shops cannot keep product in the stores fast enough which may result in higher tax collections on these sales than previously ascertained. Cash-strapped states and municipalities may view a softening stance on this topic as tangible opportunity to generate real revenue.
These events have clearly placed medical marijuana front and center as a strong, new investment category, as well as at the top of the list of discussions be legislators and consumers alike. As a result, investors should expect that medical marijuana companies and their stocks will remain under accumulation for the foreseeable future.
For more information, refer to our previous sponsored PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman
This Opportunity Research Microcap Hot Topics article was prepared for informational purposes only.
Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro cap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research on stocks in the Opportunity Research format typically have a higher risk profile, and may offer greater upside. Since May 2013, Goldman Small Cap Research has been compensated $500 per article by a third party and $4,000 for a research report service.
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information. The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com